Afina W Lemstra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6670261/publications.pdf Version: 2024-02-01



AFINA WIEMSTRA

#	Article	IF	CITATIONS
1	The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology, 2022, 269, 1375-1385.	3.6	23
2	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. Neurology, 2022, 98, .	1.1	10
3	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. Alzheimer's Research and Therapy, 2022, 14, 14.	6.2	10
4	Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	28
5	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A Europeanâ€DLB consortium project. Alzheimer's and Dementia, 2021, 17, 1277-1286.	0.8	5
6	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. Journal of Alzheimer's Disease, 2021, 82, 381-390.	2.6	8
7	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
8	Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. Neurology, 2021, 97, e930-e940.	1.1	51
9	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2021, 83, 269-279.	2.6	10
10	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	2.4	12
11	ATN classification in dementia with Lewy bodies: Association with clinical profile, cognitive decline and survival. Alzheimer's and Dementia, 2021, 17, .	0.8	1
12	Novel CSF inflammatory markers MIF and TREMâ€1 are increased in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
13	CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
14	Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An 1231-FP-CIT SPECT study. NeuroImage: Clinical, 2020, 25, 102062.	2.7	17
15	Family History is Associated with Phenotype in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2020, 73, 269-275.	2.6	2
16	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. Biomolecules, 2020, 10, 1177.	4.0	14
17	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. NeuroImage: Clinical, 2020, 28, 102504.	2.7	14
18	Functional interpretation of genetic risk loci for dementia using a protein quantitative trait loci (pQTLs) approach in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e040774.	0.8	0

AFINA W LEMSTRA

#	Article	IF	CITATIONS
19	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e041048.	0.8	2
20	Dataâ€assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. Alzheimer's and Dementia, 2020, 16, e043593.	0.8	1
21	The presence of Alzheimer's disease pathology in dementia with Lewy bodies is related to increased neocortical αâ€synuclein load and different αâ€synuclein morphology. Alzheimer's and Dementia, 2020, 16, e043949.	0.8	0
22	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Molecular Neurodegeneration, 2020, 15, 36.	10.8	46
23	Parkinsonism and Bipolar Disorder. Bipolar Disorders, 2020, 22, 413-415.	1.9	8
24	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. Movement Disorders, 2020, 35, 859-867.	3.9	33
25	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. International Journal of Molecular Sciences, 2019, 20, 4674.	4.1	26
26	Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimer's Research and Therapy, 2019, 11, 83.	6.2	23
27	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
28	Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 70, 389-397.	2.6	30
29	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. Alzheimer's Research and Therapy, 2019, 11, 25.	6.2	23
30	Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study. NeuroImage: Clinical, 2019, 22, 101755.	2.7	23
31	Metabolic patterns across core features in dementia with lewy bodies. Annals of Neurology, 2019, 85, 715-725.	5.3	47
32	Evaluation of the Digital Alzheimer Center: Testing Usability and Usefulness of an Online Portal for Patients with Dementia and Their Carers. JMIR Research Protocols, 2016, 5, e144.	1.0	47
33	Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. European Radiology, 2014, 24, 2326-2333.	4.5	50